Business Context and Reporting Period
Company: Shoulder Innovations, Inc. (NYSE: SI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A commercial-stage medical technology company focused on shoulder arthroplasty implant systems. The company operates in the United States, selling through a dedicated commercial team and independent distributors.
Key Event: The Company completed its Initial Public Offering (IPO) on August 1, 2025, issuing 5,000,000 shares at $15.00 per share. Immediately prior to the IPO, all outstanding convertible preferred stock and convertible notes converted to common stock.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Net Revenue | $11,756 | $7,454 | $32,901 | $22,898 |
| Gross Profit | $8,961 | $5,701 | $25,145 | $17,573 |
| Gross Margin | 76.2% | 76.5% | 76.4% | 76.7% |
| Operating Loss | $(7,641) | $(3,881) | $(17,797) | $(11,117) |
| Net Loss | $(8,729) | $(4,055) | $(32,587) | $(11,827) |
| Cash & Cash Equivalents | $54,934 | $6,123 | $54,934 | $6,123 |
| Marketable Securities | $82,354 | $8,921 | $82,354 | $8,921 |
| Total Liquidity | $137,288 | $15,044 | $137,288 | $15,044 |
| Long-Term Debt | $14,848 | $14,658 | $14,848 | $14,658 |
Note: Net Loss for the nine months ended September 30, 2025, includes significant non-cash charges related to the change in fair value of convertible notes ($2,217) and the Series E purchase option ($11,719).
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 57.7% year-over-year for Q3 2025 and 43.7% for the nine-month period, driven by a 22.5% increase in implant systems sold in Q3 (1,584 units vs. 1,293 units implied by prior year trends) and an expanded customer base.
- Expense Expansion: Selling, General, and Administrative (SG&A) expenses increased 77.5% in Q3 and 51.5% for the nine months, primarily due to increased headcount, commissions, legal costs related to litigation, and public company transition costs.
- Capital Structure Transformation: The Company transitioned from a private entity with significant convertible preferred stock and notes to a public company. All preferred stock and convertible notes converted to common stock upon the IPO closing in August 2025.
- Liquidity Position: Cash and marketable securities increased significantly from $15.0 million at year-end 2024 to $137.3 million at September 30, 2025, following the IPO and Series E financing.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring operating losses for the foreseeable future as it scales its commercial organization, invests in R&D, and incurs public company costs. The Company believes its current liquidity is sufficient to fund operations for at least 12 months.
Key Risks and Contingencies:
- Profitability: The Company has a history of significant net losses and an accumulated deficit of $89.6 million as of September 30, 2025. There is no assurance it will achieve or sustain profitability.
- Debt Covenants: The Company has a $15.0 million principal outstanding under the Trinity Loan Agreement. Future tranches are contingent on achieving specific annualized revenue targets ($30M by Dec 2025 and $45M by Dec 2026).
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., humeral stems, glenoid products) creates supply disruption risks.
- Legal Proceedings: Ongoing patent infringement litigation with Catalyst Orthoscience Inc., including a counterclaim filed by Catalyst against the Company.
- Seasonality: The business typically experiences lower demand in the third calendar quarter due to summer seasonality.
Investor Verification Checklist
- Debt Tranche Conditions: Verify if the Company is on track to meet the $30 million annualized revenue target required to draw the second tranche of the Trinity Loan Agreement by December 31, 2025.
- Related Party Transactions: Review the ongoing software license and consulting agreements with Genesis Software and Genesis Innovation Group, entities affiliated with the CEO and other directors.
- Inventory Management: Assess the $19.4 million inventory balance against sales velocity to evaluate obsolescence risks, particularly given the reliance on single-source suppliers.
- Legal Exposure: Monitor the status of the patent litigation with Catalyst Orthoscience for potential injunctions or damages.
- Public Company Costs: Track the trajectory of SG&A expenses to ensure they align with revenue growth as the Company transitions to a public reporting entity.